doi: 10.1158/2159-8290.CD-NB2015-158.
Epub 2015 Nov 9.
First Oncolytic Viral Therapy for Melanoma
- PMID: 26552414
- DOI: 10.1158/2159-8290.CD-NB2015-158
Item in Clipboard
First Oncolytic Viral Therapy for Melanoma
Cancer Discov.
2016 Jan.
Abstract
The FDA has approved talimogene laherparepvec, or T-VEC, to treat surgically unresectable skin and lymph node lesions in patients with advanced melanoma. T-VEC is the first oncolytic viral therapy to gain regulatory endorsement, based on data from the OPTiM study.
©2016 American Association for Cancer Research.
Similar articles
-
Talimogene laherparepvec (T-VEC) as cancer immunotherapy.Drugs Today (Barc). 2015 Sep;51(9):549-58. doi: 10.1358/dot.2015.51.9.2383044. Drugs Today (Barc). 2015. PMID: 26488034 Review.
-
The safety of talimogene laherparepvec for the treatment of advanced melanoma.Expert Opin Drug Saf. 2017 Feb;16(2):265-269. doi: 10.1080/14740338.2017.1274729. Epub 2016 Dec 28. Expert Opin Drug Saf. 2017. PMID: 27989216 Review.
-
An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions.Am J Clin Dermatol. 2020 Dec;21(6):821-832. doi: 10.1007/s40257-020-00554-8. Am J Clin Dermatol. 2020. PMID: 32767272 Review.
-
Implementing a Program of Talimogene laherparepvec.Ann Surg Oncol. 2018 Jul;25(7):1828-1835. doi: 10.1245/s10434-018-6361-5. Epub 2018 Feb 7. Ann Surg Oncol. 2018. PMID: 29417403
-
Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma.BioDrugs. 2016 Oct;30(5):461-468. doi: 10.1007/s40259-016-0189-y. BioDrugs. 2016. PMID: 27516203 Review.
Cited by
-
Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend.Front Immunol. 2018 Dec 11;9:2909. doi: 10.3389/fimmu.2018.02909. eCollection 2018. Front Immunol. 2018. PMID: 30619273 Free PMC article. Review.
-
The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives.J Hematol Oncol. 2025 Sep 2;18(1):84. doi: 10.1186/s13045-025-01732-z. J Hematol Oncol. 2025. PMID: 40898324 Free PMC article. Review.
-
MicroRNA Modification of Coxsackievirus B3 Decreases Its Toxicity, while Retaining Oncolytic Potency against Lung Cancer.Mol Ther Oncolytics. 2020 Jan 21;16:207-218. doi: 10.1016/j.omto.2020.01.002. eCollection 2020 Mar 27. Mol Ther Oncolytics. 2020. PMID: 32123721 Free PMC article.
-
Necroptotic virotherapy of oncolytic alphavirus M1 cooperated with Doxorubicin displays promising therapeutic efficacy in TNBC.Oncogene. 2021 Jul;40(29):4783-4795. doi: 10.1038/s41388-021-01869-4. Epub 2021 Jun 21. Oncogene. 2021. PMID: 34155344
-
Targeting immunogenic cell stress and death for cancer therapy.Nat Rev Drug Discov. 2024 Jun;23(6):445-460. doi: 10.1038/s41573-024-00920-9. Epub 2024 Apr 15. Nat Rev Drug Discov. 2024. PMID: 38622310 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
